Inhibrx Biosciences develops cancer treatments built from engineered proteins, now in clinical trials. It last closed at $74.18 on Nov 17, down 4.48% on the day. In the past 30 days there were 1 dark pool print totaling $986K, the largest $986K.
Only 1 firm rated INBX in the past 90 days, not enough for a consensus
Average 12-month target
$220.00
▲ 196.6% upside
Based on 1 analyst who set a price target on INBX in the past 90 days. The average target is $220.00, with a high of $220.00 and a low of $220.00, compared with the last close of $74.18.
Low $220.00Avg $220.00High $220.00
Blue marker: last close $74.18
Highest target$220.00
Average target$220.00
Lowest target$220.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 16Buy$245 → $220
HC Wainwright & Co.Initiated
Aug 24Buy$245
StifelInitiated
Apr 8Buy$150
Date
Firm
Action
Rating
Price target
Nov 16
HC Wainwright & Co.
Target lowered
Buy
$245 → $220
Aug 24
HC Wainwright & Co.
Initiated
Buy
$245
Apr 8
Stifel
Initiated
Buy
$150
Loading…
Technical Analysis
INBX · as of the Nov 17 close · updated after every close
Downtrend
The stock is 14% below its 20 day and 26% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38). The nearest support is the Pivot S1 at $71.85, and the nearest resistance the Pivot at $75.03.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 9.3%/day
Key levels
$155.2952 week high+109.3%
$95.59100 day average+28.9%
$93.5950 day average+26.2%
$93.48Swing high (Nov 11)+26.0%
$92.66200 day average+24.9%
$84.6120 day average+14.1%
$77.36Pivot R1+4.3%
$75.03Pivot+1.1%
$74.18Last close
$71.85Pivot S1−3.1%
$66.80Swing low (Oct 30)−9.9%
$57.3052 week low−22.8%
Indicators
RSI (14)
38.19
Weak, oversold below 30
Neutral
MACD
-3.30
Below its signal line
Bearish
Stochastic
37.9
Middle of its range
Neutral
ADX (14)
15.2
No clear trend
Williams %R
-72.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-93.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−8.5%
Change over 10 sessions
Bearish
ATR (14)
$6.90
Typical daily range, 9.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityHigh, 21.7%/day
Key levels
$155.2952 week high+109.3%
$95.59100 day average+28.9%
$93.5950 day average+26.2%
$93.48Swing high (Nov 11)+26.0%
$92.66200 day average+24.9%
$84.6120 day average+14.1%
$77.36Pivot R1+4.3%
$75.03Pivot+1.1%
$74.18Last close
$71.85Pivot S1−3.1%
$66.80Swing low (Oct 30)−9.9%
$57.3052 week low−22.8%
Indicators
RSI (14)
41.32
Middle of its range
Neutral
MACD
-2.34
Below its signal line
Bearish
Stochastic
21.6
Middle of its range
Neutral
ADX (14)
22.9
Weak trend
Williams %R
-88.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-115.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−32.1%
Change over 10 sessions
Bearish
ATR (14)
$16.09
Typical daily range, 21.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200–
What happened before, for INBX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how INBX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow INBX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How INBX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INBX is in one of them and how their past INBX trades turned out.
Inhibrx Biosciences is a biopharmaceutical company based in La Jolla, California. It develops biologic drug candidates, which are medicines made from proteins, using its own protein engineering platforms. Its candidates are being tested in clinical trials for cancers, including sarcomas, colorectal cancer, lung cancer and head and neck cancer. The company aims to offer these treatments to patients with serious diseases, if they are approved.